Literature DB >> 8804084

Proteases involved in the metabolism of angiotensin II, bradykinin, calcitonin gene-related peptide (CGRP), and neuropeptide Y by vascular smooth muscle cells.

R Mentlein1, T Roos.   

Abstract

To understand the regulation of the vasoactive peptides bradykinin, angiotensin II, calcitonin gene-related peptide (CGRP), and neuropeptide Y (NPY), their proteolytic catabolism by cultured rat aortic vascular smooth muscle cells and A7r5 cells was investigated. Endopeptidase-24.11 (EC 3.4.24.11, CD 10) was responsible for the final inactivation of bradykinin, angiotensin II, and CGRP, but not of NPY, which was degraded by a different metallo-endopeptidase. Exopeptidases, namely the aminopeptidases A (EC 3.4.11.7), N (EC 3.4.11.2, CD 13), and P (EC 3.4.11.9) and the carboxypeptidases M (EC 3.4.17.12) and P (EC 3.4.17.16), were important for their differential, receptor subtype-specific activation or inactivation. Aminopeptidase A and N generated angiotensins III and IV from angiotensin II. Aminopeptidase P liberated the terminal amino acids from bradykinin and NPY, yielding the Y2 receptor specific-agonist NPY(2-36). Carboxypeptidase P produced AT II(1-7) and carboxypeptidase M produced the BK1 receptor agonist [des-Arg9]bradykinin. Thus, peptidases at the surface of vascular smooth muscle cells exert a complex influence on the level of biologically active vasoactive peptides.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8804084     DOI: 10.1016/0196-9781(96)00066-6

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  22 in total

1.  Receptors mediating CGRP-induced relaxation in the rat isolated thoracic aorta and porcine isolated coronary artery differentiated by h(alpha) CGRP(8-37).

Authors:  F M Wisskirchen; D W Gray; I Marshall
Journal:  Br J Pharmacol       Date:  1999-09       Impact factor: 8.739

Review 2.  The brain renin-angiotensin system: a diversity of functions and implications for CNS diseases.

Authors:  John W Wright; Joseph W Harding
Journal:  Pflugers Arch       Date:  2012-04-26       Impact factor: 3.657

Review 3.  Inhibition of calcitonin gene-related peptide function: a promising strategy for treating migraine.

Authors:  Paul L Durham
Journal:  Headache       Date:  2008-09       Impact factor: 5.887

4.  Neuropeptide Y regulates a vascular gateway for hematopoietic stem and progenitor cells.

Authors:  Pratibha Singh; Jonathan Hoggatt; Malgorzata M Kamocka; Khalid S Mohammad; Mary R Saunders; Hongge Li; Jennifer Speth; Nadia Carlesso; Theresa A Guise; Louis M Pelus
Journal:  J Clin Invest       Date:  2017-11-13       Impact factor: 14.808

5.  Calcitonin gene-related peptide (CGRP) receptor antagonists in the treatment of migraine.

Authors:  Paul L Durham; Carrie V Vause
Journal:  CNS Drugs       Date:  2010-07       Impact factor: 5.749

6.  Neuropeptide Y bioavailability is suppressed in the hindlimb of female Sprague-Dawley rats.

Authors:  Dwayne N Jackson; Kevin J Milne; Earl G Noble; J Kevin Shoemaker
Journal:  J Physiol       Date:  2005-08-04       Impact factor: 5.182

7.  Neuropeptide Y overflow and metabolism in skeletal muscle arterioles.

Authors:  Kirk W Evanson; Audrey J Stone; Allyson L Hammond; Heidi A Kluess
Journal:  J Physiol       Date:  2011-05-09       Impact factor: 5.182

Review 8.  Dipeptidyl peptidase-4: a key player in chronic liver disease.

Authors:  Minoru Itou; Takumi Kawaguchi; Eitaro Taniguchi; Michio Sata
Journal:  World J Gastroenterol       Date:  2013-04-21       Impact factor: 5.742

9.  Kinetic study of neuropeptide Y (NPY) proteolysis in blood and identification of NPY3-35: a new peptide generated by plasma kallikrein.

Authors:  Karim Abid; Bertrand Rochat; Paul-Gerhard Lassahn; Reto Stöcklin; Sophie Michalet; Noureddine Brakch; Jean-Francois Aubert; Bilgin Vatansever; Patricia Tella; Ingrid De Meester; Eric Grouzmann
Journal:  J Biol Chem       Date:  2009-07-20       Impact factor: 5.157

Review 10.  Angiotensin receptor subtype mediated physiologies and behaviors: new discoveries and clinical targets.

Authors:  John W Wright; Brent J Yamamoto; Joseph W Harding
Journal:  Prog Neurobiol       Date:  2007-11-19       Impact factor: 11.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.